Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $913.00

Key Points

• Royal Bank of Canada raised Regeneron’s price target from $810 to $913 while maintaining a “sector perform” rating, implying 5.71% downside from the stock’s reported $968.29 price.
• Analyst sentiment remains broadly positive: Guggenheim raised its target to $1,100 and rated the stock a “buy,” while the consensus rating is “Moderate Buy” with an average price target of $890.97.
• Regeneron delivered strong quarterly results, reporting $20.07 in EPS versus $16.51 expected and $5.12 billion in revenue, up 36.3% year over year.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its price objective boosted by research analysts at Royal Bank Of Canada from $810.00 to $913.00 in a research note issued on Monday, Benzinga reports. The firm presently has a "sector perform" rating on the biopharmaceutical company's stock. Royal Bank Of Canada's price objective indicates a potential downside of 5.71% from the company's current price.

Other analysts have also issued reports about the company. Guggenheim lifted their target price on Regeneron Pharmaceuticals from $1,030.00 to $1,100.00 and gave the stock a "buy" rating in a research report on Monday. Weiss Ratings reissued a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a report on Monday, September 21st. Morgan Stanley raised their price objective on Regeneron Pharmaceuticals from $758.00 to $779.00 and gave the company an "equal weight" rating in a research note on Wednesday, October 7th. Citigroup lifted their price objective on Regeneron Pharmaceuticals from $740.00 to $825.00 and gave the stock a "neutral" rating in a report on Friday. Finally, Benchmark raised Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating and set a $185.00 target price on the stock in a research report on Tuesday, July 7th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $890.97.

Regeneron Pharmaceuticals Stock Up 4.4%

Regeneron Pharmaceuticals stock traded up $40.40 during midday trading on Monday, hitting $968.29. 637,215 shares of the stock were exchanged, compared to its average volume of 821,362. Regeneron Pharmaceuticals has a 1 year low of $591.52 and a 1 year high of $972.06. The firm has a market cap of $99.70 billion, a P/E ratio of 21.35, a P/E/G ratio of 1.57 and a beta of 0.10. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.06 and a quick ratio of 3.66. The company has a 50 day moving average price of $793.30 and a two-hundred day moving average price of $738.05.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, topping analysts' consensus estimates of $16.51 by $3.56. The firm had revenue of $5.12 billion for the quarter, compared to analyst estimates of $4.58 billion. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The firm's revenue was up 36.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $11.83 EPS. On average, sell-side analysts predict that Regeneron Pharmaceuticals will post 49.10 earnings per share for the current fiscal year.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Huda Y. Zoghbi sold 800 shares of the company's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the sale, the director owned 1,703 shares in the company, valued at $1,362,400. This represents a 31.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Andrew J. Murphy sold 4,147 shares of the company's stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the completion of the sale, the insider directly owned 47,833 shares of the company's stock, valued at $36,960,559.10. The trade was a 7.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 8,093 shares of company stock valued at $6,506,845 over the last quarter. Corporate insiders own 6.97% of the company's stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the stock. LCM Capital Management Inc lifted its holdings in shares of Regeneron Pharmaceuticals by 2.2% during the third quarter. LCM Capital Management Inc now owns 616 shares of the biopharmaceutical company's stock valued at $467,000 after purchasing an additional 13 shares during the last quarter. Arjuna Capital increased its stake in shares of Regeneron Pharmaceuticals by 3.2% in the first quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company's stock worth $353,000 after acquiring an additional 14 shares during the last quarter. Oakworth Capital Inc. boosted its position in Regeneron Pharmaceuticals by 25.0% during the third quarter. Oakworth Capital Inc. now owns 70 shares of the biopharmaceutical company's stock valued at $53,000 after purchasing an additional 14 shares during the last quarter. Geneos Wealth Management Inc. boosted its position in Regeneron Pharmaceuticals by 1.8% during the first quarter. Geneos Wealth Management Inc. now owns 835 shares of the biopharmaceutical company's stock valued at $645,000 after purchasing an additional 15 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. grew its stake in Regeneron Pharmaceuticals by 30.2% in the first quarter. Whittier Trust Co. of Nevada Inc. now owns 69 shares of the biopharmaceutical company's stock valued at $53,000 after purchasing an additional 16 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Strong Q3 results: Regeneron reported earnings of $20.07 per share, well above the $16.51 analyst consensus, while revenue rose 36% year over year to approximately $5.1 billion. Earnings growth of about 70%, strong Dupixent sales and a larger Sanofi profit share are reinforcing investor confidence. These Analysts Raise Their Forecasts On Regeneron Pharmaceuticals After Upbeat Q3 Results
• Positive Sentiment: Analysts raised targets: Guggenheim lifted its target to $1,100 and initiated a “buy” view, while JPMorgan raised its target to $1,050 with an “overweight” rating. Bank of America increased its target to $1,030 and kept a “buy” rating; broader analyst forecasts reportedly reach as high as $1,175. Regeneron Pharmaceuticals Analyst Forecasts
• Positive Sentiment: Pipeline and commercial momentum: Investors are also responding to the company’s deep pipeline, encouraging Libtayo data in high-risk skin cancer and an expanded BARDA supply agreement for an Ebola treatment. Why Regeneron Shares Are In Focus After Strong Earnings
• Positive Sentiment: Shareholder returns: Regeneron declared a quarterly dividend of $0.94 per share, payable December 3, and continues repurchases under its buyback program.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.